This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VRNA Verona Pharma PLC American Depositary Share (VRNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Verona Pharma PLC American Depositary Share Stock (NASDAQ:VRNA) Get VRNA alerts:Sign Up Key Stats Today's Range$106.91▼$106.9150-Day Range$105.91▼$106.9552-Week Range$60.50▼$106.93VolumeN/AAverage Volume2.58 million shsMarket Capitalization$9.21 billionP/E RatioN/ADividend YieldN/APrice Target$121.75Consensus RatingHold Company Overview Verona Pharma PLC, trading as American Depositary Shares on NASDAQ under the ticker VRNA, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for the treatment of respiratory diseases. The company’s primary focus is on creating first-in-class and best-in-class medicines to improve lung function and quality of life in patients suffering from chronic obstructive pulmonary disease (COPD), cystic fibrosis and other airway conditions. The company’s lead product candidate, ensifentrine, is a dual phosphodiesterase 3 and 4 inhibitor with bronchodilator and anti-inflammatory properties. Ensifentrine has completed multiple Phase 2 and Phase 3 clinical trials assessing its efficacy and safety as an inhaled therapy, both as a monotherapy and as an add-on to existing standard of care. Verona Pharma continues to work toward regulatory submissions and potential commercialization partnerships in key markets. Headquartered in London, Verona Pharma operates research and development facilities in both the United Kingdom and the United States. The company leverages collaborations with contract research organizations, clinical trial sites and academic institutions to conduct international studies designed to support regulatory filings with agencies in North America, Europe and other regions. Verona Pharma’s global reach enables it to engage a broad spectrum of respiratory specialists and patient communities. Under the leadership of Chief Executive Officer Mark Sumeray, Verona Pharma’s management team brings extensive experience in biopharmaceutical development, commercialization and strategic partnerships. The board and executive group guide the company’s efforts to advance its pipeline, secure regulatory milestones and explore business development opportunities aimed at delivering novel treatments for patients with unmet needs in respiratory care.AI Generated. May Contain Errors. Read More Verona Pharma PLC American Depositary Share Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreVRNA MarketRank™: Verona Pharma PLC American Depositary Share scored higher than 17% of companies evaluated by MarketBeat, and ranked 800th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingVerona Pharma PLC American Depositary Share has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 11 hold ratings, and 1 sell rating.Upside PotentialVerona Pharma PLC American Depositary Share has a consensus price target of $121.75, representing about 13.9% upside from its current price of $106.91.Amount of Analyst CoverageVerona Pharma PLC American Depositary Share has received no research coverage in the past 90 days.Read more about Verona Pharma PLC American Depositary Share's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Verona Pharma PLC American Depositary Share are expected to grow in the coming year, from ($1.95) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verona Pharma PLC American Depositary Share is -107.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verona Pharma PLC American Depositary Share is -107.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerona Pharma PLC American Depositary Share has a P/B Ratio of 41.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VRNA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVerona Pharma PLC American Depositary Share does not currently pay a dividend.Dividend GrowthVerona Pharma PLC American Depositary Share does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for VRNA on MarketBeat in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Verona Pharma PLC American Depositary Share insiders have not sold or bought any company stock.Percentage Held by Insiders4.80% of the stock of Verona Pharma PLC American Depositary Share is held by insiders.Percentage Held by Institutions85.88% of the stock of Verona Pharma PLC American Depositary Share is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verona Pharma PLC American Depositary Share's insider trading history. Receive VRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verona Pharma PLC American Depositary Share and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRNA Stock News HeadlinesVerona Pharma Shareholders Approve Merck AcquisitionNovember 6, 2025 | theglobeandmail.comVerona Pharma plc (VRNA)’s Shareholders Authorizes the $10 Billion Acquisition of Verona Pharma plc (VRNA); Nasdaq Trading to SuspendOctober 8, 2025 | msn.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 20 at 1:00 AM | American Alternative (Ad)Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD PortfolioSeptember 30, 2025 | insidermonkey.comHere’s What Lifted Verona Pharma (VRNA) in Q2September 25, 2025 | insidermonkey.comShareholders of Verona Pharma Approve Proposed Acquisition by MerckSeptember 24, 2025 | globenewswire.comVerona Pharma (VRNA) Rebounded from Challenging Q1September 16, 2025 | msn.comVerona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025September 16, 2025 | globenewswire.comSee More Headlines VRNA Stock Analysis - Frequently Asked Questions How were Verona Pharma PLC American Depositary Share's earnings last quarter? Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) released its earnings results on Wednesday, August, 6th. The company reported $0.13 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.14. The firm earned $103.14 million during the quarter, compared to the consensus estimate of $90.41 million. Verona Pharma PLC American Depositary Share had a negative trailing twelve-month return on equity of 21.12% and a negative net margin of 36.62%. When did Verona Pharma PLC American Depositary Share IPO? Verona Pharma PLC American Depositary Share (VRNA) raised $78 million in an initial public offering (IPO) on Thursday, April 27th 2017. The company issued 5,768,000 shares at a price of $13.50 per share. Jefferies and Stifel served as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers. What other stocks do shareholders of Verona Pharma PLC American Depositary Share own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verona Pharma PLC American Depositary Share investors own include Cisco Systems (CSCO), Philip Morris International (PM), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Home Depot (HD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/06/2025Today5/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VRNA CIK1657312 Webwww.veronapharma.com Phone011-44-0-2032834200FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Verona Pharma PLC American Depositary Share$121.75 High Price Target$170.00 Low Price Target$100.00 Potential Upside/Downside+13.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$173.42 million Net Margins-36.62% Pretax Margin-32.91% Return on Equity-21.12% Return on Assets-9.07% Debt Debt-to-Equity Ratio0.87 Current Ratio10.71 Quick Ratio10.54 Sales & Book Value Annual Sales$42.28 million Price / Sales217.94 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book41.76Miscellaneous Outstanding Shares86,190,000Free Float82,055,000Market Cap$9.21 billion OptionableOptionable Beta0.05 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:VRNA) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX did a 5-for-1 split before its IPO - here's whySpaceX just cut its share price from over $526 to roughly $105 with a 5-for-1 stock split - a move that signal...NXT Wave Research | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma PLC American Depositary Share Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma PLC American Depositary Share With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
